Your browser doesn't support javascript.
loading
Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: A Systematic Review.
Choi, Joon-Sik; Yoon, Seo Hee; Park, Hyo Jung; Lee, Soo-Youn; Kim, Yae-Jean.
Affiliation
  • Choi JS; Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Yoon SH; Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Park HJ; Department of Pharmaceutical Services, Samsung Medical Center, Seoul, Korea.
  • Lee SY; School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
  • Kim YJ; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Korean Med Sci ; 38(7): e62, 2023 Feb 20.
Article in En | MEDLINE | ID: mdl-36808548
ABSTRACT

BACKGROUND:

Teicoplanin is a glycopeptide antimicrobial that treats serious invasive infections caused by gram-positive bacteria, such as the methicillin-resistant Staphylococcus aureus. Despite some comparable advantages, there is no guideline or clinical recommendation for teicoplanin in the pediatric population, unlike vancomycin where abundant studies and the recently revised guideline on therapeutic drug level monitoring (TDM) exist.

METHODS:

The systematic review was performed in accordance with the preferred reporting items for systematic reviews. Two authors (JSC and SHY) searched PubMed, Embase, and Cochrane Library databases using relevant terms independently.

RESULTS:

Fourteen studies were finally included with a total of 1,380 patients. TDM was available in 2,739 samples collected in the nine studies. Dosing regimens varied widely, and eight studies used recommended dosing regimens. Timing for measuring TDM was mostly 72-96 hours or longer after the initiation of the first dose, which was expected to be a steady-state. The majority of studies had target trough levels of 10 µg/mL or above. Three studies reported that the clinical efficacy and treatment success rate of teicoplanin was 71.4%, 87.5%, and 88%. Adverse events associated with teicoplanin use were described in six studies with a focus on renal and/or hepatic impairment. Except for one study, no significant relation was noted between the incidence of adverse events and trough concentration.

CONCLUSION:

Current evidence on teicoplanin trough levels in pediatric populations is insufficient due to heterogeneity. However, target trough levels with favorable clinical efficacy are achievable by recommended dosing regimen in the majority of patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Staphylococcal Infections / Methicillin-Resistant Staphylococcus aureus Type of study: Guideline / Systematic_reviews Limits: Child / Humans Language: En Journal: J Korean Med Sci Journal subject: MEDICINA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Staphylococcal Infections / Methicillin-Resistant Staphylococcus aureus Type of study: Guideline / Systematic_reviews Limits: Child / Humans Language: En Journal: J Korean Med Sci Journal subject: MEDICINA Year: 2023 Document type: Article
...